Document Type
Article
Publication Date
12-20-2024
Abstract
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with a significant risk of developing hepatocellular carcinoma (HCC). Recent clinical evidence indicates the potential benefits of statins in cancer chemoprevention and therapeutics. However, it is still unclear if these drugs can lower the specific risk of HCC among patients with MASLD.
AIM: To investigate the impact of statin use on the risk of HCC development in patients with MASLD.
METHODS: A systematic review and meta-analysis of all the studies was performed that measured the effect of statin use on HCC occurrence in patients with MASLD. The difference in HCC risk between statin users and non-users was calculated among MASLD patients. We also evaluated the risk difference between lipophilic versus hydrophilic statins and the effect of cumulative dose on HCC risk reduction.
RESULTS: A total of four studies consisting of 291684 patients were included. MASLD patients on statin therapy had a 60% lower pooled risk of developing HCC compared to the non-statin group [relative risk (RR) = 0.40, 95%CI: 0.31-0.53,
CONCLUSION: Statin use lowers the risk of HCC in patients with MASLD. The higher cDDD and lipophilicity of statins correlate with the HCC risk reduction.
Recommended Citation
Tarar, Zahid Ijaz; Farooq, Umer; Inayat, Faisal; Basida, Sanket D.; Ibrahim, Faisal; Gandhi, Mustafa; Nawaz, Gul; Afzal, Arslan; Chaudhary, Ammad J.; Kamal, Faisal; Ali, Ahmad H.; and Ghouri, Yezaz A., "Statins Decrease the Risk of Hepatocellular Carcinoma in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis" (2024). Division of Gastroenterology and Hepatology Faculty Papers. Paper 110.
https://jdc.jefferson.edu/gastro_hepfp/110
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
PubMed ID
39713070
Language
English
Comments
This article is the author's final published version in World Journal of Experimental Medicine, Volume 14, Issue 4, December 2024, Article number 98543.
The published version is available at https://doi.org/10.5493/wjem.v14.i4.98543.
Copyright © The Author(s) 2024.